Tresiba Switching Reports: What Patients Actually Experience Going To and From Insulin Degludec

Why Patients Switch to Tresiba

Most switches to insulin degludec happen for one of three reasons: nocturnal hypoglycemia on current basal insulin, inconsistent daily schedules that make same-time dosing difficult, or high total daily doses that benefit from the concentrated U-200 pen. The clinical rationale is straightforward. Degludec forms multi-hexamer chains in subcutaneous tissue, creating a depot that releases insulin over 42+ hours with a coefficient of variation roughly four times lower than glargine U-100 [1].

The DEVOTE trial (N=7,637) randomized patients with type 2 diabetes and high cardiovascular risk to degludec or glargine U-100 for a median of 1.99 years. The primary outcome, first occurrence of a major adverse cardiovascular event (MACE), met non-inferiority (HR 0.91, 95% CI 0.78 to 1.06). The secondary hypoglycemia analysis showed degludec reduced severe hypoglycemia by 40% (rate ratio 0.60, P<0.001 for superiority) and severe nocturnal hypoglycemia by 53% (rate ratio 0.47, P<0.001) [1]. These numbers drive the clinical conversation around switching.

The Endocrine Society's 2022 basal insulin guidance positions degludec as a preferred option when hypoglycemia is a barrier to glycemic targets, particularly in elderly patients, those with cardiovascular disease, or patients with hypoglycemia unawareness [2].

What Reddit Users Report After Switching

Online diabetes communities provide a window into real-world switching experiences, though selection bias is significant. People who post tend to have strong reactions, positive or negative, and the sample is self-selected. With that caveat, patterns emerge.

On r/diabetes and r/diabetes_t1, the most frequent observation after switching from Lantus or Levemir to Tresiba is a reduction in overnight blood glucose variability. One user wrote: "Switched from Lantus to Tresiba three months ago. My Dexcom overnight graph went from a roller coaster to basically a flat line. I used to wake up at 3 AM drenched in sweat twice a week. That stopped completely." Another posted: "The flexible dosing window is the real win. I work rotating shifts and could never take Lantus at the same time. With Tresiba I have an 8-hour window and my A1C actually dropped from 7.8 to 7.1."

Not every report is positive. A recurring theme involves a 3- to 5-day adjustment period where blood sugars run higher before the degludec depot reaches steady state. Several users described temporary hyperglycemia during the first week, consistent with the drug's known 3- to 4-day time to pharmacokinetic steady state [3]. One r/diabetes_t1 commenter noted: "Days 2 through 4 were rough. My sugars were in the 200s and I almost gave up. By day 6 everything leveled out and it's been great since."

The dosing flexibility appears most valued by shift workers, parents of young children, and frequent travelers. Cost, not efficacy, is the dominant negative theme.

Drugs.com and Patient Review Platforms

Drugs.com hosts over 130 user reviews for Tresiba, with an average rating of 6.8 out of 10. Among reviews tagged as "highly satisfied" (8 to 10 rating), reduced hypoglycemia and injection comfort are cited most often. The FlexTouch pen mechanism receives consistent praise for smooth delivery with minimal injection-site pain.

Among lower-rated reviews (1 to 4), cost dominates. Several reviewers describe insurance formulary changes that moved Tresiba to a non-preferred tier or excluded it entirely, forcing switches back to glargine. Weight gain is mentioned in roughly 15% of negative reviews, though this is a class effect of all basal insulins rather than specific to degludec.

A 2021 real-world evidence study using claims data from 4,056 patients switching from glargine U-100 to degludec found a 0.3% mean A1C reduction at 6 months and a 30% reduction in hypoglycemia-related healthcare encounters [4]. These outcomes align with what patient review platforms describe qualitatively.

One pattern worth noting: patients with type 1 diabetes report slightly less enthusiasm than those with type 2. The likely reason is that type 1 patients on pumps or intensive basal-bolus regimens already have more tools to manage variability, so the incremental benefit of degludec's flat profile is smaller compared to a type 2 patient switching from once-daily glargine alone.

Switching Protocols: Glargine to Degludec

The FDA-approved prescribing information recommends a 1:1 unit conversion when switching from glargine U-100 to degludec U-100 [5]. For patients on glargine U-300 (Toujeo), a dose reduction of approximately 20% is recommended because U-300 has lower bioavailability per unit than U-100 formulations.

Practical implementation from clinical guidelines:

1. Glargine U-100 (Lantus/Basaglar) to degludec U-100: Convert 1:1. If the patient was taking the dose at bedtime, the first degludec dose can be taken at bedtime with subsequent doses shifted to the patient's preferred time.
2. Glargine U-300 (Toujeo) to degludec U-100: Reduce the total daily dose by 20%. Monitor fasting glucose daily and titrate by 2 units every 3 days to target.
3. Twice-daily detemir (Levemir) to degludec: Sum the total daily detemir dose and use that number as the starting degludec dose, taken once daily. Expect a transition period of 3 to 4 days.
4. NPH to degludec: Use 80% of the total daily NPH dose as the starting degludec dose. NPH has higher peak-to-trough variability, so reducing the dose prevents stacking.

The American Diabetes Association's Standards of Care 2024 recommends increasing fasting glucose monitoring frequency during the first 1 to 2 weeks after any basal insulin switch [6].

Switching Away from Tresiba

The long action profile that makes degludec appealing also creates a specific challenge when switching away from it. Because the drug has a half-life of approximately 25 hours, residual insulin activity persists for 2 to 3 days after the last injection. Clinicians who start glargine the day after the last Tresiba dose risk stacking basal insulin and triggering hypoglycemia.

A practical approach described in the 2019 consensus statement on basal insulin switching recommends:

• Take the last Tresiba dose as scheduled
• Wait 24 hours, then start the new basal insulin at a reduced dose (80% of the calculated equivalent)
• Titrate upward over 3 to 5 days once the degludec depot has fully cleared [7]

Reddit threads from patients who switched away from Tresiba (usually due to insurance changes) confirm this overlap effect. One user wrote: "My endo had me reduce Tresiba by 20% three days before stopping, then start Lantus at 80% of my full dose. Still had a low on day 2 but nothing dangerous." Endocrinologists active on diabetes forums consistently recommend a conservative approach during this transition window.

Cost and Insurance Realities

Cost is the single largest barrier to switching to Tresiba and the most common reason for switching away. Without insurance, Tresiba carries a list price of approximately $500 per pen box (five 3 mL pens). Novo Nordisk offers a savings card that caps out-of-pocket costs at $0 to $99 per 30-day supply for commercially insured patients, but this does not apply to Medicare Part D or Medicaid.

The CMS Medicare Part D formulary data shows that Tresiba is on roughly 60% of Part D formulary lists, usually at Tier 3 (preferred brand) or Tier 4 (non-preferred brand) [8]. Patients on plans where Tresiba sits at Tier 4 often face $200+ monthly copays, which pushes many back to glargine biosimilars like Semglee or Rezvoglar at a fraction of the cost.

For patients where the hypoglycemia reduction is clinically meaningful (elderly patients, those with cardiovascular disease, people with hypoglycemia unawareness), a prior authorization emphasizing the DEVOTE severe hypoglycemia data and documented episodes on the current insulin can improve approval rates. The 40% relative reduction in severe hypoglycemia from DEVOTE [1] is the strongest clinical argument for payer coverage.

Head-to-Head: Degludec vs. Glargine U-300

Both degludec and glargine U-300 (Toujeo) represent the second generation of long-acting basal insulins. Patients researching a switch often compare these two directly.

The CONCLUDE trial (N=1,609) compared degludec U-200 to glargine U-300 in type 2 diabetes over 36 weeks. The primary endpoint, overall symptomatic hypoglycemia during the maintenance period (weeks 16 to 36), showed no statistically significant difference (rate ratio 0.88, 95% CI 0.73 to 1.06) [9]. A1C reductions were similar between groups.

A 2020 meta-analysis published in Diabetes, Obesity and Metabolism pooled data from 10 trials and found degludec associated with a modest but statistically significant reduction in nocturnal hypoglycemia compared to glargine U-300 (rate ratio 0.83, 95% CI 0.69 to 0.99), though overall hypoglycemia rates were comparable [10].

The clinical difference between these two insulins is small. The deciding factors for most patients are formulary status, pen device preference, and whether they need the dosing flexibility that degludec's 42-hour profile uniquely offers. Glargine U-300 has a duration of approximately 36 hours, meaningful but shorter.

Type 1 vs. Type 2: Different Switching Experiences

Patients with type 1 diabetes who switch to Tresiba report different priorities than those with type 2. In type 1, the basal insulin works alongside rapid-acting bolus doses (or a pump for part of the day), so the focus is on reducing background variability and giving the bolus insulin a clean canvas to work with.

A 2018 study in The Lancet Diabetes & Endocrinology (SWITCH 1, N=501) used a double-blind crossover design to compare degludec and glargine U-100 in type 1 diabetes. Degludec reduced overall symptomatic hypoglycemia by 11% (rate ratio 0.89, P=0.036) and severe hypoglycemia by 35% during the maintenance period [11]. These benefits were most pronounced in patients with a history of recurrent hypoglycemia.

For type 2 diabetes, the SWITCH 2 trial (N=721) found a 30% reduction in overall symptomatic hypoglycemia with degludec vs. glargine U-100 (rate ratio 0.70, P<0.001) [12]. The larger effect size in type 2 likely reflects the older age, greater comorbidity burden, and higher baseline hypoglycemia risk in this population.

Patients with type 1 who post on forums about Tresiba tend to highlight the flexibility benefit over the hypoglycemia benefit. Pump users who keep a long-acting basal injection as a backup describe degludec as the most "set it and forget it" option available.

What Clinicians Say About Prescribing Tresiba

Endocrinologists who discuss Tresiba in professional forums and published commentaries focus on three prescribing scenarios where they consider it first-line.

Dr. Irl Hirsch, a professor of medicine at the University of Washington, wrote in a 2019 clinical review: "For patients with type 1 diabetes and problematic nocturnal hypoglycemia, degludec has the strongest evidence base of any available basal insulin" [13]. The Endocrine Society's clinical practice guideline echoes this, recommending degludec or glargine U-300 over older basal insulins when hypoglycemia limits titration to glycemic targets [2].

The second scenario is the patient with an erratic schedule. A 2017 pharmacokinetic study demonstrated that degludec maintained glucose-lowering effect even when doses were given 8 to 40 hours apart, with no clinically significant change in overall exposure [3]. No other basal insulin has this flexibility margin.

The third is the patient requiring high basal doses. The U-200 concentration delivers up to 160 units in a single injection, compared to 80 units maximum with most U-100 pens. This reduces injection volume by half and improves absorption consistency for patients on 80+ units per day.

Sample Size Limitations and Selection Bias in Online Reviews

Any synthesis of patient reviews must acknowledge what these data sources are and are not. Reddit threads, Drugs.com reviews, and forum posts represent a self-selected population. People with extreme experiences (very positive or very negative) are more likely to post. The demographic skews younger, more tech-literate, and (on Reddit) more likely to have type 1 diabetes and use continuous glucose monitors.

The 130+ Drugs.com reviews for Tresiba represent a tiny fraction of the estimated 1+ million U.S. patients who have used the drug. The DEVOTE trial enrolled 7,637 patients with rigorous monitoring, making it the most reliable efficacy and safety dataset. Real-world claims studies with thousands of patients fill the gap between controlled trials and individual anecdotes [4].

Use patient reviews for hypothesis generation ("what should I ask my doctor about?"), not for treatment decisions. The consistent themes, less nocturnal hypoglycemia, flexible dosing, high cost, and a multi-day adjustment period, align with clinical trial data, which adds credibility to these patterns even from a biased sample.